Intravenous Immunoglobulin in Autoimmune Encephalitis in Adults –A Randomised Double-Blind Placebo-Controlled Trial.
The ENCEPH-IG trial is a study led by investigators from the University of Liverpool looking at whether or not early treatment with Intravenous Immunoglobulin improves recovery in autoimmune encephalitis.
Autoimmune encephalitis is inflammation and swelling of the brain caused by the body’s own immune defence system. It affects about 1 in 100,000 people per year in the UK. The symptoms can include abnormal behaviour, memory problems and seizures. Some patients recover completely, but in others it can cause death or severe disability.
Autoimmune encephalitis is treated with steroids, which reduce inflammation and swelling. If patients are not improving, intravenous immunoglobulin (IVIG) is often also given, usually after a couple of weeks. IVIG is a protein product extracted from the blood of healthy donors. It is given through a drip into a vein each day for five days and is used for other diseases that affect the nervous system.
Some doctors think that if IVIG is used from the start of treatment, patients may recover more quickly and have less side effects from the illness. While IVIG may help patients it can have side effects, including blood clots or allergic reactions, is expensive and may not help recovery. Currently it is used in about 50% of patients with autoimmune encephalitis. The ENCEPH-IG trial (Intravenous immunoglobulin in autoimmune encephalitis in adults) is a study looking at whether or not early treatment with IVIG improves recovery.
The aims of the trial are:
- To work out whether, in adults with autoimmune encephalitis, early treatment with IVIG leads to a different time to recovery and improves the outcome.
- To carry out scientific studies to better understand the disease processes in autoimmune encephalitis and see how IVIG affects them.
Design and methods
ENCEPH-IG is an individually randomised controlled trial of 356 adults: half will receive IVIG, and the other half will receive a placebo. The study will be carried out at approximately 50 hospitals in the Brain Infections UK network.
Participants who meet the entry criteria will be randomised in a ratio of 1:1. It is double blinded, meaning neither the patients nor their medical staff will know what treatment they have received. In addition, all patients will receive the standard steroid treatment.
|Start date||1 Apr 2020|
|End date||30 Apr 2026|